Controversies in NEN : An ENETS position statement on unresolved clinical scenarios and emerging approaches with somatostatin analogues
Journal of Neuroendocrinology · 2026-11 · 38 (11)
DOI: 10.1111/jne.70313 ↗Abstract
Abstract Somatostatin analogues (SSAs) are the cornerstone of treatment for patients with neuroendocrine tumours (NETs), with established anti‐secretory activity in functioning NETs and anti‐proliferative activity in grade 1 and 2 (Ki‐67 levels, up to 10%) gastro‐entero‐pancreatic NETs. However, several clinically relevant scenarios regarding their role still remain insufficiently addressed by available guidance, including the following: patient selection for dose‐escalation or interval‐shortening after disease progression, their anti‐proliferative effect in tumours with a > 10% Ki‐67 index, their role in pulmonary carcinoids, Multiple Endocrine Neoplasia (MEN1)‐related pancreatic NETs and uncommon neuroendocrine neoplasms (NENs), their adjuvant use after surgery, and their continuation beyond disease progression, as well as the presence of predictive biomarkers, quality‐of‐life endpoints, and emerging somatostatin receptor (SSTR)‐targeted strategies. This manuscript addresses 10 practical questions regarding SSA use beyond established indications. The available evidence supports dose‐intensification mainly for improved hormonal symptom control and, in selected patients, temporary disease stabilisation, while objective tumour responses remain uncommon. Anti‐proliferative effects may also be observed in some grade 2 NETs with a Ki‐67 index higher than 10%, albeit with diminishing activity in the presence of increasing proliferative activity, whereas it is limited in grade 3 tumours. Evidence in pulmonary carcinoids, MEN1‐related pancreatic NETs, and other uncommon somatostatin receptor (SSTR)‐positive NETs remains heterogeneous, and mostly based on small or non‐randomised studies. In contrast, routine adjuvant treatment after complete tumour resection is not currently supported, although retrospective studies suggest a potential benefit in selected patients with resected pancreatic NETs at high risk of recurrence. Quantitative SSTR imaging, tissue SSTR2 expression and circulating molecular markers are promising tools for patient selection, but none is currently validated for routine predictive use. New formulations and SSTR‐directed agents with receptor‐binding properties distinct from those of conventional SSAs are expected to broaden future treatment options, although their clinical value will require prospective confirmation.
EUVIMED